Upgrade to SI Premium - Free Trial

Incyte's (INCY) "Opzelura Miss is Likely to Weigh on Shares" - BMO Capital Keeps Stock at Market Perform with $81 Price Target Post Q2 Earnings

August 2, 2022 7:44 AM
BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $81.00 price target on Incyte (NASDAQ: INCY), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments

Next Articles